美国类风湿关节炎治疗中甲氨蝶呤使用不足:全国处方实践分析
结果显示口服MTX起始剂量偏低,44%患者维持原剂量,换药时87%加用或换用生物制剂,仅13%转为皮下MTX;2009至2012年口服MTX平均剂量仅从15.3mg/周微增至15.9mg/周,皮下MTX使用率从13%升至16%。结论认为MTX在RA治疗中存在剂量不足、疗程不够及未充分利用皮下给药的问题。
要点
- 口服MTX起始后44%患者维持原剂量,换药时87%加用或换用生物制剂。
- 启用生物制剂前口服MTX平均剂量仅15.3±5mg/周,剂量偏低。
- 2009至2012年皮下MTX使用率仅从13%升至16%,增长有限。
核心结论
- MTX在RA治疗中使用不足,表现为剂量不理想、疗程不够及未采用皮下给药。
- 2009与2012年队列比较,口服MTX剂量和皮下MTX使用仅 marginal 增加。
研究设计与样本
- 识别2009年和2012年新使用MTX的RA患者,收集用药、剂量、人口学及合并症数据。
主要发现
- 有5年随访数据的患者中,2009年口服MTX起始者35,640例,44%继续维持该剂量。
- 研究期间20,041例换药患者中,87%加用或换用生物制剂,13%从口服转为皮下MTX。
- 启用生物制剂前口服MTX平均剂量为15.3±5mg/周。
- 2009至2012年口服MTX平均剂量从15.3mg/周增至15.9mg/周。
- 口服MTX失败后皮下MTX使用率从13%升至16%(P<0.0001)。
关键数值与推荐
- 口服MTX平均剂量:2009年15.3mg/周,2012年15.9mg/周。
- 皮下MTX使用率:2009年13%,2012年16%(P<0.0001)。
- 换药患者中87%加用或换用生物制剂,13%转为皮下MTX。
- 启用生物制剂前口服MTX平均剂量15.3±5mg/周。
临床怎么用
- 应关注RA患者MTX剂量优化,避免过早加用生物制剂。
- 口服MTX疗效不足时,应考虑转为皮下MTX而非直接换用生物制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) due to its effectiveness, tolerability, and cost. This study examines MTX prescribing practices in the US from 2009 to 2014. METHODS: Symphony Health Solutions, which covers 274 million patients in the US, was used to identify patients diagnosed with RA who were naive to MTX in 2009 and 2012. Data were collected, including medication use and doses, demographics, and medical comorbidities. RESULTS: Of the patients who had 5-year followup data available, oral MTX was started in 35,640 in 2009, and 44% continued taking this dose during the followup. Of the 20,041 patients who changed therapy during the study period, 87% had the addition of or switched to a biologic agent, while 13% were changed from oral to subcutaneous (SC) MTX. The mean oral dose prior to the start of a biologic agent was 15.3 ± 5 mg/week. A comparison of 2009 with 2012 showed a modest increase in the mean dose of oral MTX from 15.3 mg/week to 15.9 mg/week, as well as a small but statistically significant (P < 0.0001) increase in the use of SC MTX after failure of oral MTX from 13% to 16% of patients. CONCLUSION: MTX is underutilized in the treatment of RA with suboptimal dosing, inadequate duration of therapy, and failure to use SC administration. The comparison of MTX use between the 2009 and the 2012 cohorts demonstrates only a marginal increase in the dose of oral MTX and the use of SC MTX.
引用
- Rohr MK, Mikuls TR, Cohen SB, et al. Underuse of Methotrexate in the Treatment of Rheumatoid Arthritis: A National Analysis of Prescribing Practices in the US. Arthritis Care Res (Hoboken). 2017. PMID: 27863180. doi:10.1002/acr.23152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。